Dance/movement therapy as a holistic approach to diminish health discrepancies and promote wellness for people with schizophrenia: a review of the literature.

dance/movement therapy embodiment healthcare disparities interoception mind-body connection neurobiology schizophrenia

Journal

F1000Research
ISSN: 2046-1402
Titre abrégé: F1000Res
Pays: England
ID NLM: 101594320

Informations de publication

Date de publication:
2023
Historique:
accepted: 28 07 2023
medline: 21 8 2023
pubmed: 18 8 2023
entrez: 18 8 2023
Statut: epublish

Résumé

Individuals with a diagnosis of schizophrenia face a myriad of obstacles to wellness, beginning with diagnostic discrepancies including over- and misdiagnoses on the schizophrenia spectrum. People with schizophrenia experience profound amounts of stigmatization from the general population, their healthcare providers, and even themselves. Such stigmatization creates a barrier for wellness, poorer prognoses, and often limits adherence to physical and mental healthcare. Moreover, it can exacerbate the already stifling symptomatology of their diagnoses, including specific bodily-related symptomatology. Oftentimes, a diagnosis of schizophrenia disrupts one's relationship with their body including a diminished mind-body connection, decreased interoceptive awareness, and thus unsuccessful intra- and interpersonal relationships. Some recent research suggests the use of mind-body therapies, however, if these practices are internalizing, they may not be appropriate for people with schizophrenia experiencing more acute symptomatology excluding them from treatment. Dance/movement therapy (DMT) is an embodied psychotherapeutic treatment option that can support participants in improving mind-body connection, social relationships, and self-regulatory skill development. Research on DMT has shown promising results for people with schizophrenia, however such research is limited and would benefit from increased studies that particularly measure the effects of DMT on mind-body connection and increased interoception for people with schizophrenia. Moreover, integrative and collaborative treatment models that couple DMT and biofeedback may further our understanding of the physiological and neurological effects of DMT interventions for people with schizophrenia and beyond. This review will examine the recent literature on health inequities for people with schizophrenia, their specific body-based disruptions and needs, and DMT as a promising treatment model, particularly when coupled with biofeedback.

Identifiants

pubmed: 37593363
doi: 10.12688/f1000research.127377.2
pmc: PMC10429376
doi:

Types de publication

Journal Article Review Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

33

Informations de copyright

Copyright: © 2023 Biondo J.

Déclaration de conflit d'intérêts

No competing interests were disclosed.

Références

J Nerv Ment Dis. 2021 Feb 1;209(2):114-122
pubmed: 33141785
Health Serv Res. 2019 Apr;54(2):346-355
pubmed: 30687928
Psychiatry Res. 2022 Dec;318:114970
pubmed: 36436323
Psychiatry Res. 2017 Jan;247:73-78
pubmed: 27871030
Acta Psychiatr Scand. 2015 Aug;132(2):109-21
pubmed: 25958971
Qual Health Res. 2016 Feb;26(3):330-44
pubmed: 26063604
Front Psychol. 2019 Aug 20;10:1806
pubmed: 31481910
Eur J Neurosci. 2021 Dec;54(12):8364-8380
pubmed: 33999462
Neurosci Biobehav Rev. 2022 Jan;132:757-773
pubmed: 34823914
Clin Psychol Psychother. 2021 Jan;28(1):24-38
pubmed: 32539160
Schizophr Bull. 2019 Sep 11;45(5):1060-1067
pubmed: 30551180
Virtual Mentor. 2014 Sep 01;16(9):674-90
pubmed: 25216304
Clin Rehabil. 2014 Dec;28(12):1172-9
pubmed: 24849796
Eur J Psychotraumatol. 2023;14(2):2225152
pubmed: 37427835
Psychiatry Res. 2020 Aug;290:113068
pubmed: 32474069
Schizophr Res. 1996 Aug 23;21(2):117-24
pubmed: 8873779
Am J Psychiatry. 2021 Jul;178(7):579-581
pubmed: 34270341
Schizophr Res. 2019 Oct;212:4-5
pubmed: 31451298
World Psychiatry. 2017 Oct;16(3):308-315
pubmed: 28941119
Front Hum Neurosci. 2016 Jul 27;10:379
pubmed: 27512369
Psychiatry Res. 2019 Sep;279:295-305
pubmed: 30879703
BMC Fam Pract. 2009 May 09;10:32
pubmed: 19426545
Int J Cardiol. 2016 Oct 1;220:553-7
pubmed: 27390986
Adm Policy Ment Health. 2016 Sep;43(5):650-662
pubmed: 26411564
Front Psychol. 2021 Apr 29;12:634079
pubmed: 33995190
Front Hum Neurosci. 2016 Jun 17;10:305
pubmed: 27378895
Schizophr Res. 2020 Aug;222:267-273
pubmed: 32461087
BMC Psychiatry. 2021 Sep 7;21(1):443
pubmed: 34493245
Front Psychol. 2019 May 03;10:936
pubmed: 31130889
Schizophr Res. 2021 Feb;228:43-50
pubmed: 33434731
Front Psychiatry. 2022 Jan 26;12:798530
pubmed: 35153863
Am J Public Health. 2022 Apr;112(4):624-632
pubmed: 35319958
Psych J. 2019 Mar;8(1):110-121
pubmed: 30912624
EMBO Rep. 2016 Sep;17(9):1250-3
pubmed: 27470237
Schizophr Res. 2019 Oct;212:15-25
pubmed: 31378557
Curr Opin Psychiatry. 2019 Sep;32(5):388-393
pubmed: 31135491
J Psychiatr Res. 2021 Oct;142:48-53
pubmed: 34320455
J Ment Health. 2022 Oct;31(5):613-623
pubmed: 32401072

Auteurs

Jacelyn Biondo (J)

Family and Community Medicine, Thomas Jefferson University, Philadelphia, PA, 19107, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH